SMARCA4 deficiency in glioblastoma: Mitochondrial transfer from MSCs and the clinical dilemma in targeting the tumor microenvironment
Related Experiment Video
Updated: Feb 17, 2026
MitoCeption: Transferring Isolated Human MSC Mitochondria to Glioblastoma Stem Cells
Published on: February 22, 2017
Fan Yang1, Lin Chen1, Yuchen Shi2
1Department of Neurosurgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua 321000, Zhejiang, China.
Introduction:
SMARCA4, a pivotal transcription activator regulating chromatin structure, gene expression, and cellular energy metabolism, has well-documented roles in various cancers. However, its specific function in glioblastoma (GBM) pathogenesis remains underexplored. This study investigates the correlation between SMARCA4 expression and GBM progression, with a focus on the tumor microenvironment.
Materials And Methods:
Single-cell RNA sequencing analyzed dynamic niche cell proportion shifts (e.g., mesenchymal stromal cells, MSCs) during GBM progression. SMARCA4 knockdown was executed in MSCs for in vitro functional evaluations, while an immunodeficient xenograft model was utilized to assess the impact of SMARCA4-deficient MSCs on in vivo GBM progression. Mechanistic studies focused on microtubule-dependent mitochondrial transfer in IDH mutant/wild-type tumors.
Results:
SMARCA4 was identified as a critical MSC regulator. Its knockdown altered MSC/GBM cell behavior in vitro, accelerated in vivo GBM progression, and worsened outcomes. SMARCA4-deficient MSCs enhanced GBM growth via mitochondrial transfer, altering MSC proliferative phenotype but increasing mitochondrial metabolic capacity.
Discussion:
Our findings highlight SMARCA4's critical role in regulating MSC function within the GBM microenvironment. Targeting SMARCA4-mediated mitochondrial transfer in MSCs may represent a novel therapeutic strategy for GBM.
Insights
SMARCA4 regulates mesenchymal stromal cells (MSCs) in glioblastoma (GBM). Targeting SMARCA4-mediated mitochondrial transfer in MSCs offers a potential new therapy for GBM.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- SMARCA4 is a transcription activator involved in various cancers.
- Its role in glioblastoma (GBM) pathogenesis is not well understood.
- This study explores SMARCA4 expression in relation to GBM progression and the tumor microenvironment.
Purpose of the Study:
- To investigate the function of SMARCA4 in glioblastoma.
- To determine the correlation between SMARCA4 expression and GBM progression.
- To elucidate the role of SMARCA4 in the GBM tumor microenvironment.
Main Methods:
- Single-cell RNA sequencing to analyze niche cell proportions.
- SMARCA4 knockdown in mesenchymal stromal cells (MSCs) for in vitro studies.
- Immunodeficient xenograft models to assess in vivo GBM progression.
- Mechanistic studies on microtubule-dependent mitochondrial transfer.
Main Results:
- SMARCA4 is a critical regulator of MSCs in GBM.
- SMARCA4 knockdown in MSCs altered cell behavior and accelerated GBM progression in vivo.
- SMARCA4-deficient MSCs promoted GBM growth through mitochondrial transfer, impacting MSC phenotype and mitochondrial metabolism.
Conclusions:
- SMARCA4 plays a crucial role in regulating MSC function within the GBM microenvironment.
- Targeting SMARCA4-mediated mitochondrial transfer in MSCs presents a potential novel therapeutic strategy for GBM.
More Related Videos
09:18Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds
Published on: July 16, 2018
08:56Modeling Mitochondrial Disease Using Brain Organoids: A Focus on Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes
Published on: October 10, 2025
